Search research articles
Contact Us
Filters
Showing results (221-230 of 424) with videos related to
Page
of 43
Sort By:
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary
P Klein, G Prolla, R Wallach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2000
Maintenance chemotherapy in advanced ovarian cancer
M S Piver, F M Muggia, M F Brady, et al.
Annals of Internal Medicine
|
December 1, 1970
Hypercalcemia in cancer
J Horton, K B Olsen, F M Muggia, et al.
The New England Journal of Medicine
|
December 14, 1978
Sounding board. Waiting for a bus: Does it explain age-dependent differences in response to chemotherapy of early breast cancer?
M Rozencweig, M Zelen, D D Von Hoff, et al.
Gynecologic Oncology
|
August 7, 2004
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
Franco M Muggia, John A Blessing, Ramon McGehee, et al.
Annals of Internal Medicine
|
June 1, 1977
Cis-diamminedichloroplatinum (II). A new anticancer drug
M Rozencweig, D D von Hoff, M Slavik, et al.
Cancer Treatment Reports
|
October 1, 1977
Time relationship between last dose of daunorubicin and congestive heart failure
D D Von Hoff, M Layard, M Rozencweig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 1998
A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas
A A Garcia, R A Kempf, M Rogers, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
June 20, 1997
Determination of hydroxyurea in plasma and peritoneal fluid by high-performance liquid chromatography using electrochemical detection
M P Pujari, A Barrientos, F M Muggia, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1979
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials
J S Penta, M Rozencweig, A M Guarino, et al.
Page
of 43
Search research articles
Search
Showing results (221-230 of 424) with videos related to
Sort By:
Page
of 43
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary
P Klein, G Prolla, R Wallach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2000
Maintenance chemotherapy in advanced ovarian cancer
M S Piver, F M Muggia, M F Brady, et al.
Annals of Internal Medicine
|
December 1, 1970
Hypercalcemia in cancer
J Horton, K B Olsen, F M Muggia, et al.
The New England Journal of Medicine
|
December 14, 1978
Sounding board. Waiting for a bus: Does it explain age-dependent differences in response to chemotherapy of early breast cancer?
M Rozencweig, M Zelen, D D Von Hoff, et al.
Gynecologic Oncology
|
August 7, 2004
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
Franco M Muggia, John A Blessing, Ramon McGehee, et al.
Annals of Internal Medicine
|
June 1, 1977
Cis-diamminedichloroplatinum (II). A new anticancer drug
M Rozencweig, D D von Hoff, M Slavik, et al.
Cancer Treatment Reports
|
October 1, 1977
Time relationship between last dose of daunorubicin and congestive heart failure
D D Von Hoff, M Layard, M Rozencweig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 1998
A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas
A A Garcia, R A Kempf, M Rogers, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
June 20, 1997
Determination of hydroxyurea in plasma and peritoneal fluid by high-performance liquid chromatography using electrochemical detection
M P Pujari, A Barrientos, F M Muggia, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1979
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials
J S Penta, M Rozencweig, A M Guarino, et al.
Page
of 43